Brentuximab ADC to treat sALCL in ChinaJune 10, 2020
Takeda China announced that brentuximab vedotin (Adcetris) has been officially approved by China’s National Medical Products Administration (NMPA) for use in adult patients with relapsed or refractory systemic anaplastic large cell lymphoma (sALCL) or CD30-positive Hodgkin lymphoma.
Brentuximab is an antibody-drug conjugate (ADC) comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent, monomethyl auristatin E (MMAE). The ADC employs a linker system that is designed to be stable in the bloodstream but to release MMAE upon internalisation into CD30-positive tumour cells.
Brentuximab injection for intravenous infusion has received FDA approval for six indications including for sALCL in combination with cyclophosphamide, doxorubicin, and prednisone.